Associated Papers
Gastrointestinal Stromal Tumors: Molecular Mechanisms of Drug Resistance and Advances in Therapeutic Strategies.
Jingnuo D et al.
Journal of Gastroenterology and Hepatology, 2026
MITF regulates autophagy and extracellular vesicle cargo in gastrointestinal stromal tumors.
Proaño-Pérez E et al.
Molecular Biomedicine, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial).
Falkenhorst J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Clinicopathological characteristics of progressive gastrointestinal stromal tumors and heterogeneity analyses of secondary mutations.
Li J et al.
The Oncologist, 2025
MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective study.
Cai X et al.
Bmc Cancer, 2024
Genomic and transcriptomic landscape of human gastrointestinal stromal tumors.
Xie F et al.
Nature Communications, 2024
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
He C et al.
Current Treatment Options in Oncology, 2024
Overcoming Secondary Mutations of Type II Kinase Inhibitors.
Wang X et al.
Journal of Medicinal Chemistry, 2024
KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST.
Zhou S et al.
Cell Communication and Signaling : Ccs, 2024
Golgi retention and oncogenic KIT signaling via PLCγ2-PKD2-PI4KIIIβ activation in gastrointestinal stromal tumor cells.
Obata Y et al.
Cell Reports, 2023
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor.
Venkataraman V et al.
The Oncologist, 2023
Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study.
Zhou Y et al.
The Oncologist, 2023
MOZ and Menin-MLL Complexes Are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor.
Hemming ML et al.
Cancer Discovery, 2022
Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial.
Jeffers M et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022
Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers.
George S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2022
Molecular Portrait of GISTs Associated With Clinicopathological Features: A Retrospective Study With Molecular Analysis by a Custom 9-Gene Targeted Next-Generation Sequencing Panel.
Qian H et al.
Frontiers in Genetics, 2022
Monitoring Circulating Tumor DNA During Surgical Treatment in Patients with Gastrointestinal Stromal Tumors.
Johansson G et al.
Molecular Cancer Therapeutics, 2021
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial.
Wagner AJ et al.
Jama Oncology, 2021
Nationwide evaluation of mutation-tailored treatment of gastrointestinal stromal tumors in daily clinical practice.
Steeghs EMP et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021
The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia.
Qin YZ et al.
Blood Cancer Journal, 2021
Mutational spectrum and precision oncology for biliary tract carcinoma.
Lin J et al.
Theranostics, 2021
The V654A second-site KIT mutation increases tumor oncogenesis and STAT activation in a mouse model of gastrointestinal stromal tumor.
Zhang JQ et al.
Oncogene, 2020
Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors.
Zeng C et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2020
Phase and context shape the function of composite oncogenic mutations.
Gorelick AN et al.
Nature, 2020
Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.
Banks E et al.
Science Translational Medicine, 2020
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
Hamid AB et al.
Cancers, 2020
Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib.
Zhu G et al.
Cell & Bioscience, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
The rs17084733 variant in the KIT 3' UTR disrupts a miR-221/222 binding site in gastrointestinal stromal tumour: a sponge-like mechanism conferring disease susceptibility.
Ravegnini G et al.
Epigenetics, 2019
Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.
Hemming ML et al.
Cancer Research, 2019
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
Serrano C et al.
British Journal of Cancer, 2019
LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma.
Klug LR et al.
Oncogene, 2019
Computational analysis reveals histotype-dependent molecular profile and actionable mutation effects across cancers.
Heim D et al.
Genome Medicine, 2018
Hydroxysteroid 11-Beta Dehydrogenase 1 Overexpression with Copy-Number Gain and Missense Mutations in Primary Gastrointestinal Stromal Tumors.
Li CF et al.
Journal of Clinical Medicine, 2018
BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor.
Tsai HJ et al.
Cancer Science, 2018
Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
Chen W et al.
Cancer Research, 2017
Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions.
Li K et al.
Oncotarget, 2017
Sustained Mutant KIT Activation in the Golgi Complex Is Mediated by PKC-θ in Gastrointestinal Stromal Tumors.
Kim WK et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
Tang CM et al.
Oncotarget, 2016